Merck PE Ratio 2006-2018 | MRK

Current and historical p/e ratio for Merck (MRK) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Merck PE ratio as of January 22, 2019 is 17.73.
Merck PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-01-22 75.83 57.89
2018-09-30 70.94 $1.31 54.15
2018-06-30 60.70 $0.56 108.39
2018-03-31 54.05 $0.64 84.45
2017-12-31 55.35 $0.93 59.52
2017-09-30 62.45 $1.67 37.39
2017-06-30 62.07 $2.47 25.13
2017-03-31 61.08 $2.19 27.89
2016-12-31 56.18 $2.03 27.67
2016-09-30 59.11 $1.96 30.16
2016-06-30 54.16 $1.82 29.76
2016-03-31 49.33 $1.63 30.27
2015-12-31 48.83 $1.56 31.30
2015-09-30 45.26 $3.75 12.07
2015-06-30 51.72 $3.42 15.12
2015-03-31 51.82 $3.86 13.43
2014-12-31 50.80 $4.10 12.39
2014-09-30 52.62 $1.82 28.91
2014-06-30 50.98 $1.89 26.97
2014-03-31 49.65 $1.51 32.88
2013-12-31 43.43 $1.46 29.75
2013-09-30 40.94 $1.66 24.66
2013-06-30 39.59 $1.84 21.52
2013-03-31 37.34 $2.12 17.61
2012-12-31 34.25 $2.16 15.86
2012-09-30 37.36 $2.19 17.06
2012-06-30 34.27 $2.18 15.72
2012-03-31 31.18 $2.25 13.86
2011-12-31 30.28 $2.03 14.92
2011-09-30 25.95 $1.37 18.94
2011-06-30 27.68 $0.93 29.76
2011-03-31 25.61 $0.52 49.25
2010-12-31 27.64 $0.28 98.72
2010-09-30 27.94 $2.81 9.94
2010-06-30 26.27 $4.31 6.09
2010-03-31 27.75 $4.81 5.77
2009-12-31 26.87 $5.38 5.00
2009-09-30 23.03 $3.80 6.06
2009-06-30 20.11 $2.70 7.45
2009-03-31 18.97 $2.78 6.82
2008-12-31 21.21 $3.63 5.84
2008-09-30 21.70 $2.10 10.33
2008-06-30 25.64 $2.29 11.20
2008-03-31 25.56 $2.24 11.41
2007-12-31 38.80 $1.50 25.86
2007-09-30 34.29 $2.47 13.88
2007-06-30 32.78 $2.20 14.90
2007-03-31 28.86 $2.12 13.61
2006-12-31 28.25 $2.03 13.91
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $204.560B $40.122B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $350.628B 16.44
Pfizer (PFE) United States $253.175B 14.27
Novartis AG (NVS) Switzerland $205.567B 17.62
AbbVie (ABBV) United States $134.627B 11.95
Eli Lilly (LLY) United States $123.506B 21.71
Novo Nordisk (NVO) Denmark $117.412B 19.07
Sanofi (SNY) France $104.035B 12.88
GlaxoSmithKline (GSK) United Kingdom $96.892B 13.02
AstraZeneca (AZN) United Kingdom $92.577B 11.49
Bristol-Myers Squibb (BMY) United States $81.806B 13.47